SoftBank Group’s Neumora Therapeutics NMRA Stock Holding History

SoftBank Group’s Portfolio NMRA Stock Details NMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4M	Hold	6,090,301	–	–	0.06%	24
2026 Q1	$11.9M	Sell	6,090,301 -339,419	-5%	-$880K	0.1%	23
2025 Q4	$11.5M	Sell	6,429,720 -111,470	-2%	-$244K	0.07%	22
2025 Q3	$11.9M	Hold	6,541,190	–	–	0.05%	22
2025 Q2	$4.8M	Hold	6,541,190	–	–	0.02%	25
2025 Q1	$6.54M	Hold	6,541,190	–	–	0.02%	23
2024 Q4	$69.3M	Sell	6,541,190 -1,005,726	-13%	-$12.1M	0.3%	12
2024 Q3	$99.7M	Sell	7,546,916 -100,000	-1%	-$1.17M	0.45%	10
2024 Q2	$75.2M	Hold	7,646,916	–	–	0.38%	10
2024 Q1	$105M	Hold	7,646,916	–	–	0.55%	8
2023 Q4	$130M	Hold	7,646,916	–	–	0.7%	8
2023 Q3	$108M	Buy	+7,646,916	New	+$95.6M	1.19%	8

Other funds holding NMRA

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SoftBank Group's NMRA Position: Q2 2026 in Review

SoftBank Group held its Neumora Therapeutics (NMRA) position steady in Q2 2026 at 6,090,301 shares worth $10.4M. The position accounts for 0.06% of the portfolio, ranked #24.

SoftBank Group first reported a position in NMRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $130M in Q4 2023. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

SoftBank Group held 6,090,301 shares of Neumora Therapeutics worth $10.4M as of Q2 2026.
SoftBank Group left its Neumora Therapeutics share count unchanged in Q2 2026.
Neumora Therapeutics made up 0.06% of SoftBank Group's portfolio in Q2 2026, its #24 holding.
SoftBank Group first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 12 quarters since.
SoftBank Group's Neumora Therapeutics position peaked at $130M in Q4 2023.
113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on SoftBank Group's 13F filing for Q2 2026, filed 14 Aug 2026.